Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session with its shares rising over 7% on the day. The share price rise was supported by the company’s receipt of advice from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) with regard to clinical and regulatory aspects of Dipexium's planned submission of a Marketing Authorization Application (MAA) for candidate Locilex. This also led to more shares changing hands than in a normal session. Yesterday’s rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $11.50 to $12.96 in the past one-month time frame.
Over the last 30 days, this biopharmaceutical company witnessed a mixed record of one positive and one negative estimate revision while the Zacks Consensus Estimate moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Dipexium currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the med-drugs industry is Valeant Pharmaceuticals International, Inc. (VRX) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment